Ibrutinib (Imbruvica0) is an antineoplastic that inhibits various tyrosine kinases, including Bruton tyrosine kinase. In the European Union, it is authorised, as mono-therapy or in combination with other drugs, for the treatment of some adult patients with mantle cell lymphoma, chronic lymphocytic leukaemia, or Waldenstrom's macroglobulinaemia, although without clear evidence of clinical benefit. Ibrutinib carries a risk of many, sometimes serious, adverse effects including thrombocytopenia and bleeding, neutropenia and infections, interstitial lung disease, cancer, stroke, cardiac arrhythmia and heart failure (1-3).
展开▼
